Nuo Therapeutics, Inc. has reported strong financial results for the third quarter of 2026, revealing an 80% increase in total revenues compared to the same period last year. This growth is attributed to the company's focus on regenerative therapies for chronic wound care, particularly its Aurix product. The positive financial performance comes at a critical time as Nuo navigates the competitive landscape of the surgical and medical instruments industry.
On November 16, 2026, Nuo Therapeutics, Inc. (OTCQB: AURX) disclosed its financial results for the third quarter, which ended on September 30, 2026. The company reported total revenues of approximately $1.9 million for the quarter and $4.9 million for the first nine months of 2026, marking a significant increase of 80% and 123%, respectively, compared to the same periods in 2025.
The results highlight a sequential growth in total product revenues, which increased by 5% from the second quarter of 2026. Notably, Aurix wound care revenues surged by approximately 17% sequentially, maintaining a consistent growth rate over the past six quarters. However, the company also reported a net operating loss of approximately $374,000 for the third quarter, although this was an improvement of about $166,000 compared to the same quarter in 2025.
In its filing, Nuo Therapeutics emphasized the importance of recent Medicare reimbursement rulings that have positively impacted its business outlook. The company received a reimbursement fee milestone of $250,000 under its distribution agreement with Smith+Nephew. Additionally, the final Medicare Outpatient Prospective Payment System (OPPS) reimbursement ruling for calendar year 2027 increased the national average reimbursement for Aurix treatments to approximately $2,257, a 7% increase from 2026. This is expected to enhance the demand for Aurix as the company expands its coverage for nursing home treatments effective January 1, 2027.
David Jorden, Nuo's Chief Executive and Financial Officer, commented on the broader wound care market, noting that it remains unsettled due to changes in reimbursement economics for skin substitutes and grafts. He expressed optimism about the growth opportunities in hospital settings, where Aurix revenues have seen substantial increases. Jorden stated, "The economics in hospital settings are strong, and we will continue to pursue and emphasize growth opportunities in this segment. We remain confident that autologous PRP and Aurix in particular are well positioned for continued long-term attractive growth."
Looking ahead, Nuo Therapeutics aims to reach operational breakeven while assessing opportunities to strengthen its capital structure. The company received final funding of $325,000 under its loan agreement, bringing total borrowings to $2 million. This funding is part of its strategy to support future growth.
As Nuo Therapeutics continues to navigate the evolving landscape of the surgical and medical instruments industry, its strong financial performance and strategic initiatives position it well for sustained growth in the chronic wound care market.
Read Next
Millicom launches offering of Senior Notes due 2033
MetaVia completes Phase 1 trial for DA-1726 dual-receptor agonist
Boxlight Reports Third-Quarter Financial Results
MarineMax amends SEC filing to correct financial statement date
Worthington Enterprises presents at Baird 2026 Global Industrial Conference
Axalta and Akzo Nobel Advance Merger with New Notes Offering







